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ABSTRACT
Objectives: Diclofenac-induced nephrotoxicity is caused by oxidative stress which leads to lipid peroxidation and formation of free radicals. 
Pentoxifylline can ameliorates renal tissue injury by its anti-inflammatory, antifibrotic, and antioxidant effects, so it mitigates the progression of renal 
diseases. Therefore, the aim of this study was to evaluate the nephroprotective effects of pentoxifylline on diclofenac-induced nephrotoxicity in rats.
Methods: A total of 30 male Sprague-Dawley rats were allocated into three groups, Group 1 (n=10): Rats treated with distilled water 5 ml/kg plus 
normal saline 5 ml/kg for 12 days, Group 2 (n=10): Rats treated with distilled water 5 ml/kg plus diclofenac 15 mg/kg for 12 days, and Group 3 
(n=10): Rats treated with pentoxifylline 100 mg/kg plus diclofenac 15 mg/kg for 12 days. Blood urea, creatinine, malondialdehyde (MDA), superoxide 
dismutase (SOD-1), glutathione reductase (GSH), neutrophil gelatinase associated lipocalin (NGAL), kidney injury molecules (KIM-1) vitronectin 
(VTN), integrin (ITG) , interleukin-18 (IL-18) and cystatin-C were used to measure the severity of nephrotoxicity.
Results: Diclofenac-induced nephrotoxicity led to significant elevation in blood urea, serum creatinine, MDA, IL-18, KIM-1, NGAL, serum ITG, and VTN 
with decrease of SOD-1 and GSH sera levels p<0.05. Treatment with pentoxifylline showed no significant effect on all biomarker levels compared to 
diclofenac group except on serum level KIM-1 and serum VTN, p<0.05.
Conclusion: Pentoxifylline produced significant nephroprotective effect on diclofenac-induced nephrotoxicity through modulation of inflammatory 
biomarkers.
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INTRODUCTION
Nephrotoxicity is a renal-specific situation in which the toxic metabolites 
do not excrete normally due to toxic agents and drugs [1]. Nephrotoxic 
agents lead to interstitial nephritis and glomerulonephritis. Acute 
interstitial nephritis is caused by nonsteroidal anti-inflammatory drug 
(NSAIDs) and rifampicin, while chronic interstitial nephritis is caused 
by lithium and calcineurin inhibitors [2].
Proximal renal tubular cells are susceptible to the toxic effect of different 
drugs and agents due to extended exposure and reabsorbing process. 
Nephrotoxic drugs lead to damage of the proximal renal tubules through 
stimulation of oxidative stress, impairments of mitochondrial functions, 
and interfering with reabsorbing tubular transport process [3].
Diclofenac is a NSAID belongs to the structural family of acetic acid 
derivatives. Diclofenac is used as analgesic, anti-inflammatory, and 
antipyretic agent [4].
The foremost mechanism of diclofenac is through the inhibition 
of prostaglandin-endoperoxide synthase which also called 
cyclooxygenase-2 (COX-2). Diclofenac inhibits COX-1 about 10-fold 
than COX-2. It also inhibits lipoxygenase pathway that reduces the 
production of leukotrienes and other pro-inflammatory autacoids as 
well diclofenac sodium blocks phospholipase A2 lead to broad and 
potent anti-inflammatory effect [5].
Long-term treatment with diclofenac causes dose-dependent reduction 
in the glomerular function. In addition, diclofenac induces autolysis 
that increases renal intracellular osmolality which is responsible for 
dilatations of proximal renal tubules [6].
Toxic dose of diclofenac provokes renal mitochondrial dysfunction 
through the inhibition of mitochondrial complex causes a reduction 
in adenosine triphosphate (ATP) generation and apoptosis. Thus, 
antioxidants may play a potential role in prevention of diclofenac-
induced nephrotoxicity through attenuation of free radical and 
oxidative stress effects [7].
Pentoxifylline is a xanthine derivative drug used in the treatment of 
peripheral vascular diseases [8]. Pentoxifylline has a beneficial effect 
in nephropathy through reduction of tumor necrosis factor (TNF)-α, 
proteinuria, and microalbuminuria in diabetic patients. Pentoxifylline 
inhibits leukotriene and TNF synthesis, increases intracellular cAMP, 
and decreases innate immunity and inflammation. Pentoxifylline also 
prevents the expression of mRNA levels of TNF-α and antagonize 
adenosine receptors [9].
Pentoxifylline impedes the reduction of estimated glomerular filtration 
rate (eGFR) by a mechanism independent of its effects. Pentoxifylline 
protects the kidney by inhibition of arachidonic acid metabolism. 
Pentoxifylline ameliorates renal injury through anti-inflammatory, 
antifibrotic, and antioxidant effects, so it mitigates the progression of 
renal diseases [10].
There is a positive significant relationship between pentoxifylline 
therapy and reduction in TNF-α level and albuminuria. Since TNF-α 
production occurs within the kidneys, So administration of pentoxifylline 
leads to modulation of its synthesis [11]. Pentoxifylline decreases 
proteinuria in patients with diabetic neuropathy. As well, pentoxifylline 
has the ability to reduce proteinuria by two main mechanisms. First, 
it has the ability to increase the deformability of red blood cells result 
in lowering of blood viscosity that decreases glomerular pressure and 
© 2019 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ajpcr.2019.v12i3.30829
Research Article
434
Asian J Pharm Clin Res, Vol 12, Issue 3, 2019, 433-437
 Alkuraishy et al. 
proteinuria. The second mechanism is thought to be due to the ability 
of pentoxifylline to block adenosine receptors since hyperfiltration is 
associated with high production of renal adenosine [12].
In addition, pentoxifylline ameliorates nephrotic syndrome and 
membranous glomerulonephritis. Moreover, pentoxifylline reduces 
proteinuria in patients with advanced and early-onset diabetic 
nephropathy [13].
Therefore, the aim of this study was to evaluate the nephroprotective 
effects of pentoxifylline on diclofenac-induced nephrotoxicity in rats.
METHODS
Study design
A total of 30 male Sprague-Dawley rats were used, which were gained 
from the National Center for Drug Control and Research. Rats age ranged 
from 3 to 4 months and their body weight ranged from 200 to 400 g. The 
animals were isolated as three rats in each sterilized cage and placed 
with suitable temperature of 22–25°C and artificial 12/12 light-dark 
cycle. They left for 1 week for adaptation without any intervention with 
free access to normal chow pellets and water. This study was permitted 
by specific Scientific Adjudicators and Ethical Committee in the Medical 
Board College of Medicine, Al-Mustansiriya, Baghdad, Iraq. Humane 
care for animals was according to the guide to the care and the use of 
laboratory animal. All drugs were purchased from private pharmacy, 
diclofenac sodium ampule 75 mg/3 ml (Almiral®, Czech Republic), and 
pentoxifylline 400 mg tablet (Trental®, Canada). The study protocol and 
method for induction of nephrotoxicity were according to Singh et al. 
method [14].
Group 1 (n=10): Rats treated with distilled water 5 ml/kg plus normal 
saline 5 ml/kg for 12 days. Group 2 (n=10): Rats treated with distilled 
water 5 ml/kg plus diclofenac 15 mg/kg for 12 days. Group 3 (n=10): 
Rats treated with pentoxifylline 100 mg/kg plus diclofenac 15 mg/kg 
for 12 days.
At the 13th day of the study, animals were sacrificed and blood samples 
were centrifugated at 3500 rpm/15 min for biochemical analysis.
Assessment of renal injury biomarkers
Renal injury was evaluated by measuring specific biomarkers including 
blood urea, serum creatinine and biomarkers of nephrotoxicity including 
malondialdehyde (MDA), superoxide dismutase (SOD), glutathione 
reductase (GSH), Neutrophil Gelatinase Associated Lipocalin (NGAL), 
kidney injury molecules (KIM-1), interleukin-18 (IL-18), vitronectin 
(VTN), integrin (ITG) and cystatin-C were measured by enzyme-linked 
immunosorbent assay kit methods according to the instruction of the 
manufacture.
Assessment of anthropometric variables
Length was measured by graduated tape measure from nose to the anus 
(naso-anal length in cm). Rat body weight was measured by specific 
digital balance in gram. Body mass index was measured by specific 
equation, body mass index (BMI) = BW (grams)/length (cm)2 [15].
Estimated eGFR was measured according to Schwartz formula, 
eGFR=k × height (cm)/serum creatinine (mg/dl), K=0.55 [16].
Statistics
Data of the present study were presented as mean ± SD. Unpaired 
Student’s t-test was used to detect the level of significance between 
control and treated groups. P value was regarded as statistically 
significant when it <0.05.
RESULTS
During diclofenac-induced nephrotoxicity, rat body weight was increased 
to 286.87±27.24 g compared to the control group 268.00±25.01g but 
not significant, p=0.20. Rat BMI was increased significantly in diclofenac 
group compared to the control, p=0.0003. Blood urea was raised 
significantly in diclofenac group (70.5±12.53 mg/dl) compared to the 
control group (41.83±7.46 mg/dl), p=0.0003, also serum creatinine 
increased significantly (1.52±0.49 mg/dl) compared to control 
group (0.7±0.14 mg/dl), p=0.0019. The estimated GFR was reduced 
significantly in diclofenac group (7.59±1.7 ml/min/1.73) compared to 
the control (16.89±4.21 ml/min/1.37), p=0.0001.
Regarding the oxidative stress and endogenous antioxidant capacity, 
there was insignificant increase in the MDA serum levels in diclofenac 
group (427.65±210.39 ng/ml) compared to the control group 
(289.85±44.18 ng/ml), p=0.14; also, both SOD-1 and GSH serum level 
were reduced in diclofenac group compared to control group p=0.20 
and p=0.49, respectively.
Concerning the inflammatory and pro-inflammatory biomarkers in 
diclofenac-induced nephrotoxicity, IL-18 serum level was increased but 
not significant in diclofenac group from 29.79±3.27 to 14.88±3.02 pg/ml 
compared to control group, p=0.36. Moreover, KIM-1 was significantly 
raised in diclofenac group (269.03±29.61 pg/ml) compared to the 
control group (73.78±16.29), p=0.0001. However, serum levels of 
NGAL, ITG, and VTN were insignificantly increased (p>0.05) compared 
to the control group as shown in Table 1.
Indeed, cystatin-C serum level was insignificantly increased during 
induction of nephrotoxicity by diclofenac from 0.024±0.0005 ng/ml in 
the control group to 0.0277±0.009 ng/ml in the experimental group, 
p=0.33 (Fig. 1).
The potential effect of pentoxifylline during diclofenac-induced 
nephrotoxicity showed a significant reduction in BMI (0.55±0.01g/ 
cm²) compared to diclofenac group (0.64±0.03 g/cm²), p=0.0001. 
Pentoxifylline significantly improves estimated GFR from 7.59±1.7 ml/
min/1.73 in diclofenac group to 12.22±4.33 ml/min/1.37, p=0.0138. 
In addition, pentoxifylline reduced KIM-1 from 269.03±29.61 pg/ml in 
diclofenac group to 71.6±31.36 pg/ml significantly p=0.0001. As well, 
pentoxifylline reduced vitronectin serum level to 1.35±0.699 ng/ ml 
compared to 2.47±0.89ng/ml in diclofenac group, p=0.0142. 
Accordingly, pentoxifylline illustrated insignificant effect on the other 
renal biomarkers p>0.05, as shown in Table 2.
In addition , pentoxifylline  produced insignificant effect in reduction 
cystatin-c  serum levels, p=0.67 (Fig. 2).
DISCUSSION
Diclofenac-induced nephrotoxicity has been broadly studied in the 
past and become one of imperative and usual model of drug-induced 
nephrotoxicity. However, numerous controversies are still about the 
major mechanism of toxicity and the latent role of different biomarkers 
concerning inflammatory and pro-inflammatory cytokines [17].
The present study illustrated significant nephrotoxicity which induced by 
diclofenac through elevation of blood urea and serum creatinine compared 
to the control in the experimental rats as supported by Alabi et al. [18].
Oxidative stress, free radical generations, lipid peroxidations, and 
diminution of endogenous antioxidant capacity are the chief mechanisms 
of diclofenac-induced nephrotoxicity as explained by Hickey et al. study 
that demonstrated a high dose of diclofenac administration lead to 
significant lipid peroxidation through elevation of MDA and reduction 
of SOD-1. As a result, free radicals lead to mitochondrial damage and 
reduction in the ATP formation causing DNA damage which eventually 
leads to acute renal injury [19]. However, in the present study, there was 
insignificant elevation in MDA serum level and insignificant reduction 
in the antioxidant capacity (SOD-1, GSH), respectively, which might due 
to insufficient diclofenac dose, small sample size, or short duration of 
experimental study.
Many cytokines are elevated during diclofenac-induced nephrotoxicity 
that reflects the inflammatory process in the renal tissues. Bunel 
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et al. study showed that IL-18, NGAL, ITG, and VTN sera levels were 
significantly increased within a short period of renal injury (within h) 
and return to the normal levels within few days due to partial 
regeneration of damaged renal tubules [20]. This may explain the 
insignificant elevated levels of these biomarkers in the present study. 
In addition, renal biomarkers are subjected to different inconsistency 
including dynamic of their excretion, diurnal variations, and baseline 
assessment as supported by Harrill et al. study that confirmed the 
variable results of the present study [21].
On the contrary, Fu et al. illustrated significant role of vitronectin and 
integrin in the detection of diabetes-induced renal injury [22]. As well, 
Kim et al. study showed that elevation of NGAL serum level is correlated 
with renal tubular damage in diabetic nephropathy; thus, NGAL reflects 
independently early proximal renal tubules damage [23]. Furthermore, 
KIM-1 was significantly elevated in the present study compared to the 
control. Lan et al. study confirmed a significant elevation of KIM-1 in 
cadmium-induced nephrotoxicity [24].
Harman et al. study confirmed that cystatin-C is a surrogate biomarker 
for acute renal injury and should be incorporated in the estimation 
of GFR [25], but cystatin-C serum levels in diclofenac-induced 
nephrotoxicity of the present study were elevated insignificantly 
compared to the control which might due to small sample size, 
biomarker variability, and short duration of the study. These factors 
may contribute into the insignificant elevation of cystatin-C in 
diclofenac-induced nephrotoxicity in rats’ model of the current study.
Pentoxifylline once co-administrated with diclofenac it created a significant 
reduction in rat BMI compared to the diclofenac group due to the reduction 
of diclofenac-induced nephrotoxicity and amelioration of edematous status 
through enhancement of rat GFR, given that, pentoxifylline improves renal 
functions with significant protection of renal tubules against diclofenac-
induced renal tubules injury. However,  blood urea and serum creatinine 
were not reduced  by the effect of pentoxifylline.
Table 1: Effect of diclofenac on the anthropometric variables, biochemical and inflammatory biomarkers in diclofenac-induced 
nephrotoxicity
Variable Control (n=10) Diclofenac (n=10) p
Weight (g) 268.00±25.01 286.87±27.24 0.20
Height (cm) 21.50±0.83 21.51±0.53 0.19
BMI (g/cm2) 0.57±0.02 0.64±0.03 0.0003*
Blood urea (mg/dL) 41.83±7.46 70.50±12.53 0.0003*
Serum creatinine (mg/dL) 0.70±0.14 1.52±0.49 0.0019*
Estimated GFR (ml/min/1.73) 16.89±4.21 7.59±1.7 0.0001*
MDA (ng/mL) 289.85±44.18 427.65±210.39 0.14
SOD-1 (pg/mL) 48.12±32.92 30.62±15.54 0.20
GSH (μg/mL) 15.94±2.39 14.88±3.02 0.49
IL-18 (pg/mL) 29.79±3.27 39.37±24.74 0.36
KIM-1 (pg/mL) 73.78±16.29 269.03±29.61 0.0001*
NGAL (pg/mL) 15.78±3.07 18.76±4.13 0.16
ITG (ng/mL) 1.47±0.71 2.11±0.65 0.10
VTN (ng/mL) 1.99±0.11 2.47±0.89 0.21
*p<0.01; unpaired t-test, BMI: Body mass index; GFR: Glomerular filtration rate; MDA: Malondialdehyde; SOD-1: Superoxide dismutase; GSH: Glutathione reductase; 
IL-18: Interleukin-18; KIM-1: Kidney injury molecule-1; Cys-C: Cystatin; NGAL: Neutrophil gelatinase-associated lipocalin; ITG: Integrin; vitronectin
Table 2: Effect of pentoxifylline on the anthropometric variables, biochemical and inflammatory biomarkers in diclofenac-induced 
nephrotoxicity
Variable Diclofenac (n=10) Pentoxifylline (n=10) p
Weight (g) 286.87±27.24 281.37±29.712 0.70
Height (cm) 21.00±0.53 22.50±0.92 0.0013*
BMI (g/cm2) 0.64±0.03 0.55±0.01 0.0001*
Blood urea (mg/dL) 70.50±12.53 64.75±27.48 0.59
Serum creatinine (mg/dL) 1.52±0.49 1.012±0.52 0.06
Estimated GFR (ml/min/1.73) 7.59±1.7 12.22±4.33 0.0138
MDA (ng/mL) 427.65±210.39 283.75±56.89 0.08
SOD-1 (pg/mL) 30.62±15.54 42.00±27.52 0.32
GSH (μg/mL) 14.88±3.02 20.64±8.89 0.10
IL-18 (pg/mL) 39.37±24.74 29.41±12.99 0.33
KIM-1 (pg/mL) 269.03±29.61 71.6±31.36 0.0001*
NGAL (pg/mL) 18.76±4.13 16.78±3.79 0.33
ITG (ng/mL) 2.11±0.65 2.01±1.81 0.88
VTN (ng/mL) 2.47±0.89 1.35±0.699 0.00142*
*p<0.01; p<0.05 unpaired t-test, BMI: Body mass index; GFR: Glomerular filtration rate; MDA: Malondialdehyde; SOD-1: Superoxide dismutase; GSH: Glutathione 
reductase; IL-18: Interleukin-18; KIM-1: Kidney injury molecule-1; Cys-C: Cystatin; NGAL: Neutrophil gelatinase-associated lipocalin; ITG: Integrin; vitronectin
Fig. 1: Cystatin-C serum levels in diclofenac-induced 
nephrotoxicity
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Pentoxifylline in the present study produced insignificant attenuation 
of diclofenac-induced oxidative stress. This not corresponds with a 
recent study that confined the renoprotective effect of pentoxifylline 
through attenuation of oxidative stress in rate model study. The 
insignificant findings might due to short duration of the experimental 
study or inadequate dose of pentoxifylline to create a sufficient effect 
on oxidative stress since the duration of Ozturk et al. study was 4 weeks 
to show the protective effect of pentoxifylline on oxidative renal 
damage [26].
Indeed, pentoxifylline reduced KIM-1 and VTN serum levels significantly, 
but it produced insignificant effect on the other biomarkers compared 
to the diclofenac group. Thus, nephroprotective effect of pentoxifylline 
was mainly due to the reduction of KIM-1 in the present study as 
supported by Soni et al. study [27].
In addition, pentoxifylline produced insignificant reduction in 
cystatin-C serum levels in diclofenac-induced nephrotoxicity. Cystatin-C 
serum levels are correlated with the severity of acute renal injury 
and nephrotoxicity, so it used as a proxy biomarker for diagnosis and 
prognosis of acute renal injury [28]. However, pentoxifylline reduced 
cystatin-C in the present study but not significant level which might due 
to low dose or short period of the study which limits the cytoprotective 
effect of pentoxifylline as confirmed by Selvin et al. study that illustrated 
the variability in renal biomarkers [29].
CONCLUSION
Pentoxifylline produced significant nephroprotective effect on 
diclofenac-induced nephrotoxicity through modulation of inflammatory 
biomarkers.
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